[go: up one dir, main page]

CA2503380A1 - Compositions pharmaceutiques renfermant de la venlafaxine - Google Patents

Compositions pharmaceutiques renfermant de la venlafaxine Download PDF

Info

Publication number
CA2503380A1
CA2503380A1 CA002503380A CA2503380A CA2503380A1 CA 2503380 A1 CA2503380 A1 CA 2503380A1 CA 002503380 A CA002503380 A CA 002503380A CA 2503380 A CA2503380 A CA 2503380A CA 2503380 A1 CA2503380 A1 CA 2503380A1
Authority
CA
Canada
Prior art keywords
formulation
water insoluble
venlafaxine
linked
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002503380A
Other languages
English (en)
Inventor
Adel Penhasi
Mila Gomberg
Avi Avramoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dexcel Pharma Technologies Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/280,084 external-priority patent/US6703044B1/en
Application filed by Individual filed Critical Individual
Publication of CA2503380A1 publication Critical patent/CA2503380A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une formulation retard à libération progressive comprenant un noyau présenté sous la forme d'une pastille comprimée et un enrobage externe entourant le noyau renfermant la venlafaxine ou un sel acceptable sur le plan pharmaceutique de celle-ci, au moins un agent de commande de décharge et un désintégrant; l'enrobage externe comprenant un véhicule hydrophobe insoluble dans l'eau et une matière particulaire insoluble dans l'eau mais hydrophile.
CA002503380A 2002-10-25 2003-10-23 Compositions pharmaceutiques renfermant de la venlafaxine Abandoned CA2503380A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/280,084 2002-10-25
US10/280,084 US6703044B1 (en) 2002-10-25 2002-10-25 Venlafaxine formulations
IL158,493 2003-10-20
IL15849303A IL158493A0 (en) 2002-10-25 2003-10-20 Pharmaceutical compositions containing venlafaxine
PCT/IL2003/000862 WO2004037226A2 (fr) 2002-10-25 2003-10-23 Compositions pharmaceutiques renfermant de la venlafaxine

Publications (1)

Publication Number Publication Date
CA2503380A1 true CA2503380A1 (fr) 2004-05-06

Family

ID=32178938

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002503380A Abandoned CA2503380A1 (fr) 2002-10-25 2003-10-23 Compositions pharmaceutiques renfermant de la venlafaxine

Country Status (4)

Country Link
EP (1) EP1558222A2 (fr)
AU (1) AU2003274655A1 (fr)
CA (1) CA2503380A1 (fr)
WO (1) WO2004037226A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1711169B1 (fr) * 2004-02-04 2007-05-09 Alembic Limited Minicomprimes revetus a liberation prolongee de chlorhydrate de venlafaxine
WO2007102169A1 (fr) * 2006-03-08 2007-09-13 Jubilant Organosys Limited Préparation pharmaceutique de venlafaxine à libération prolongée et son procédé de fabrication
WO2007112574A1 (fr) * 2006-04-03 2007-10-11 Isa Odidi Composition de venlafaxine à libération prolongée
EP2612681B1 (fr) * 2010-08-31 2019-01-30 Toray Industries, Inc. Agent de revêtement pour préparation solide pharmaceutique, formulation de film pharmaceutique, et préparation solide pharmaceutique revêtue
ES3008933T3 (en) 2015-09-29 2025-03-25 Merz Pharmaceuticals Llc Sustained release compositions of 4-aminopyridine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
EP1474123A1 (fr) * 2002-01-03 2004-11-10 LEK Pharmaceuticals D.D. Formulation pharmaceutique a liberation controlee contenant de la venlafaxine

Also Published As

Publication number Publication date
EP1558222A2 (fr) 2005-08-03
WO2004037226A3 (fr) 2004-07-08
WO2004037226B1 (fr) 2004-09-10
AU2003274655A1 (en) 2004-05-13
AU2003274655A8 (en) 2004-05-13
WO2004037226A2 (fr) 2004-05-06

Similar Documents

Publication Publication Date Title
US6703044B1 (en) Venlafaxine formulations
JP4072597B2 (ja) 持続性製剤
RU2325163C2 (ru) Композиции с пролонгированным высвобождением, включающие ламотригин
US20090208572A1 (en) Oral controlled release tablet
JPH061716A (ja) 活性成分の長期放出性を有する投薬形
WO2011111027A2 (fr) Formulation de comprimé oral dispersible à libération retardée
JP2001507359A (ja) 徐放性シサプリドミニ錠剤製剤
US20070122480A1 (en) Sustained release formulations
US20090258067A1 (en) Modified release composition of at least one form of venlafaxine
US9820936B2 (en) Oral controlled release pharmaceutical compositions of Bepotastine
CA2503380A1 (fr) Compositions pharmaceutiques renfermant de la venlafaxine
KR100762846B1 (ko) 서방성 제제
WO2009080061A1 (fr) Formulation pharmaceutique à libération prolongée contenant un agent antimuscarinique et un agent mouillant et procédé de préparation correspondant
US10420764B2 (en) Pharmaceutical formulation of N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-YL]-4-[(3R,5S)-3 ,5-dimethylpiperazin-1-YL] benzamide
WO2020101586A1 (fr) Formulations de propivérine à libération contrôlée
CN1232386A (zh) 弱酸药物的结肠运送
WO2009087663A2 (fr) Comprimé oral enrobé à libération contrôlée
KR20050114921A (ko) 방출제어형 약제학적 조성물
WO2007035816A2 (fr) Compositions de paroxétine
US20080206338A1 (en) Controlled release formulations of an alpha-adrenergic receptor antagonist
CA2635949A1 (fr) Formule a liberation controlee d'acide divalproique et ses derives
WO2024162929A1 (fr) Formulation à libération contrôlée de propivérine
TW201609196A (zh) 控制釋放製劑及其製備方法
WO2006136927A1 (fr) Preparation a liberation prolongee comprenant de la venlafaxine

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead